Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

ESMO2014 update on Abiraterone

Abiraterone and prednisone in men with CRPC prior to docetaxel earlier showed improved progression-free survival but follow up was too short to meet the co-primary endpoint of the COU-AA302 study: overall survival.

Now longer follow up data from the COU-AA302 study in mentioned population were presented at ESMO2014 by Dr. Charles Ryan. At 49.2m follow up abiraterone prolonged overall survival with 4.3m to 34.7m. This is an interesting observation since subsequent treatments were frequent and 44% of men in the control arm later received abiraterone.

Early abiraterone and prednisone in men with CRPC provides a significant overall survival benefit despite the frequent need of subsequent treatments.


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


URO ONCO is made possible by an unrestricted educational grant from:

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.

The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.